Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)
The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.
Canyon-I-Pilot Trial a dose-ranging study of bolus-only Desirudin in patients undergoing PCI - CANYON-PCI pilot study
/ Not yet recruitingNot Applicable A dose-ranging study of bolus-only Desirudin in patients undergoing PCI
100 Clinical Results associated with Canyon Pharmaceuticals, Inc.
0 Patents (Medical) associated with Canyon Pharmaceuticals, Inc.
100 Deals associated with Canyon Pharmaceuticals, Inc.
100 Translational Medicine associated with Canyon Pharmaceuticals, Inc.